# CatalYm

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/catalym

- Industry: Biotechnology
- Headquarters: Germany
- Website: www.catalym.com
- Total disclosed funding: $261M
- Latest round: Series D (Jul 9, 2024)
- Investors on record: 14

## About

CatalYm GmbH, based in Germany, specializes in developing innovative immunotherapy solutions for cancer treatment, focusing on GDF-15 as a mechanism to overcome resistance to existing therapies.Founded in 2016, CatalYm GmbH is dedicated to developing therapies that target GDF-15, a key protein involved in cancer treatment resistance. The company, headquartered in Germany, has successfully raised funds through various rounds, including its latest Series D round, which raised USD 150.000 mn, bringing its total funds raised to USD 150.000 mn. The CEO is Phil L'Huillier, and the founder is Jörg Wischhusen, who has significant experience in the healthcare industry.CatalYm focuses on the development of innovative immunotherapy solutions that specifically target GDF-15 to counteract resistance to cancer therapies. Its flagship product, Visugromab, functions as a monoclonal antibody designed to neutralize GDF-15, thus reinstating effective anti-tumor immune responses in patients with solid tumors. This treatment addresses immune suppression in cancer patients who have not responded to prior therapies, particularly for those resistant to checkpoint inhibitors. CatalYm's offerings target oncology professionals and institutions engaged in cancer treatment across Europe and North America.CatalYm's revenue model is built on partnerships and collaborations within the pharmaceutical and biotech sectors, particularly around the clinical development of its lead product, Visugromab. The company collaborates with healthcare institutions, research organizations, and industry partners to facilitate clinical trials and the commercialization of its therapies. Revenue generation is structured through strategic collaborations, encompassing milestone payments and royalties based on product development stages, which reflect the company's focus on B2B relationships in the healthcare ecosystem.CatalYm GmbH aims to expand its product portfolio with new therapies targeting GDF-15 and anticipates launching additional products in the coming years. The company is also exploring expansion into new geographic markets, particularly targeting regions in Europe and North America. The recent funding from MaasInvest will be utilized to support these initiatives, enhancing the company’s capabilities in clinical development and market adoption of its immunotherapy products.

## Funding rounds

- Series D, Jul 9, 2024, $150M — Canaan Partners, Novartis Venture Fund, Gilde Healthcare, Hostplus, Brandon Capital Partners, Forbion, BioGeneration Ventures, Vesalius Biocapital, Omega Funds, Stichting Bewaarder BSR, Jeito Capital, Bioqube Ventures
- Series C, Nov 17, 2022, $52M — Novartis Venture Fund, Brandon Capital Partners, Forbion, BioGeneration Ventures, Vesalius Biocapital, Bayern Kapital, Coparion, Hostplus, Jeito Capital
- Series B, Nov 10, 2020, $59M — Novartis Venture Fund, Forbion, BioGeneration Ventures, Vesalius Biocapital, Bayern Kapital, Coparion
- Seed, Aug 5, 2016 — Forbion, BioGeneration Ventures

## Investors

- Forbion (https://capitalatlas.ai/funds/forbion) — Seed, Series B, Series C, Series D
- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Seed, Series B, Series C, Series D
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B, Series C, Series D
- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series B, Series C, Series D
- Bayern Kapital (https://capitalatlas.ai/funds/bayern-kapital) — Series B, Series C
- Coparion (https://capitalatlas.ai/funds/coparion) — Series B, Series C
- Brandon Capital Partners (https://capitalatlas.ai/funds/brandon-capital-partners) — Series C, Series D
- Hostplus — Series C, Series D
- Jeito Capital (https://capitalatlas.ai/funds/jeito-capital) — Series C, Series D
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series D
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series D
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series D
- Stichting Bewaarder BSR — Series D
- Bioqube Ventures (https://capitalatlas.ai/funds/bioqube-ventures) — Series D